Clinical Trial Update: A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) [Phase 2]

View source ↗

Summary

Phase 2 trial of ABBV-8E12 in progressive supranuclear palsy was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• ABBV-8E12 (ABBV-8E12)

Snippet

Sponsor: AbbVie | Conditions: Progressive Supranuclear Palsy | Phase 2 | Status: TERMINATED | Results posted: 2021-02-03